$ABSI reports record-breaking year with ten new active programs and breakthroughs in drug creation
Absci, a generative AI drug creation company, exceeded its 2022 full-year guidance by launching 10 new Active Programs and anticipates at least ten more in 2023. Its strategic initiatives have strengthened its platform, talent, and infrastructure. Absci's generative AI capabilities and wet lab technologies have created breakthroughs in drug creation, demonstrating its ability to create and validate de novo antibodies using zero-shot generative AI. The company has focused on expanding its capabilities to develop an internal pipeline of assets. Absci's financial results show an increase in revenue of $44.6M for 2022, with sufficient funding into late 2025 for strategic initiatives and near-term inflection points, promising a bright outlook for investors.